Roche CEO Bullish on U.S. Drug Market
Roche shares gain after the company's CEO says he's 'fully dedicated' to the key U.S. market.
Roche (RHHBY) shares traded higher in Zurich on Wednesday after the company's CEO said he was bullish on developments in the U.S. despite President Donald Trump's planned changes to the country's health care system.
Group sales for 2016 came in at Sfr50.58 billion ($51.05 billion), up 4% from 2015, on a constant currency basis, and core operating profit hit Sfr18.42 billion, or Skr14.53 per share on a diluted basis.
Roche shares extended their three-month gain to 3%.
CEO Severin Schwan said, "I believe that the life sciences industry plays a major role in the U.S. beyond the innovations we bring to patients."
